A new HIV drug reduced viral replication and increased immune cells in individuals with advanced, drug-resistant HIV infection. Used in combination with existing HIV medications, the drug is a promising strategy for patients who have run out of effective treatment options, the researchers said.
A team of astronomers has made a surprising discovery: 12.5 billion years ago, the most opaque place in the universe contained relatively little matter.
Scientists have presented research on a curious cosmic phenomenon known as ‘whistlers’ — very low frequency packets of radio waves that race along magnetic field lines. The study provides new insights into the nature of whistlers and space plasmas and could one day aid in the development of practical plasma technologies with magnetic fields, including spacecraft thrusters that use charged particles as fuel.
Researchers at the University of Chicago have discovered that in elephants, the tumor-suppressor gene p53 awakens a dormant gene, which goes on to kill cancer precursor cells. They believe the discovery could be used to develop drugs that mimic this process.
A triumvirate of aging-focused biotechs and researchers—the AI company Insilico Medicine, the portfolio-based startup Juvenescence and the nonprofit Buck Institute—have formed a new joint venture to develop small molecules for a novel target in a bid to extend life spans.
Evotec AG and Haplogen GmbH have been long-term collaboration partners. The companies announced that Haplogen will enter into a multi-year drug discovery and development deal with Bayer AG to focus on pulmonary diseases like chronic obstructive pulmonary disease (COPD).
Shares of Realm Therapeutics have plunged more than 50 percent this morning after the company announced its Phase II atopic dermatitis drug failed to distinguish itself from the control arm in the trial.
Western government agencies have been warning of an increase in cyber espionage from nefarious black hats and governments for years. The targets have typically been government and financial installations. But a new warning suggests that biotechnology could be a key target for cyber hackers.
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—…
Acorda Therapeutics Chief Technology Officer Rick Batycky is leaving the company to take over the helm of an unnamed biotechnology company.